Gilead Sciences Review

About Gilead Sciences

Gilead Sciences: A Leading Biopharmaceutical Company

Gilead Sciences, Inc. is a research-based biopharmaceutical company that has been at the forefront of developing innovative medicines for over three decades. The company was founded in 1987 by Michael Riordan, a medical doctor and entrepreneur who saw an opportunity to develop new treatments for life-threatening diseases.

Today, Gilead Sciences is one of the largest biopharmaceutical companies in the world, with operations in more than 35 countries and a portfolio of products that includes some of the most important therapies for HIV/AIDS, hepatitis B and C, cancer, and other serious illnesses.

The company's mission is to improve the lives of patients around the world by developing innovative medicines that address unmet medical needs. To achieve this goal, Gilead invests heavily in research and development (R&D), with more than $3 billion spent on R&D each year.

One of Gilead's key strengths is its expertise in antiviral therapies. The company has developed several groundbreaking treatments for HIV/AIDS over the years, including Truvada®, Atripla®, Complera®/Eviplera®, Stribild®/Genvoya®, Descovy®, Odefsey®/Symtuza™/, Biktarvy™/, Vemlidy®/, Epclusa®/Harvoni®, Sovaldi®, and Vosevi™/. These drugs have transformed HIV treatment from a death sentence to a manageable chronic condition.

In addition to its work on HIV/AIDS, Gilead has also made significant contributions to hepatitis B and C treatment. The company's hepatitis C drugs Sovaldi®and Harvoni® were game-changers when they were introduced in 2013-2014 because they offered cure rates above 90% with fewer side effects than previous treatments.

Beyond antivirals, Gilead has also made strides in oncology with its CAR-T cell therapy Yescarta™/. This therapy uses genetically modified immune cells to attack cancer cells directly. It was approved by FDA as first CAR-T cell therapy for adults with certain types of non-Hodgkin lymphoma (NHL) after two or more lines of systemic therapy.

Another area where Gilead is making progress is inflammation & respiratory diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), ulcerative colitis (UC) etc., where it recently acquired Immunomedics Inc., which brought Trodelvy™ into their portfolio - an antibody-drug conjugate used for treating metastatic triple-negative breast cancer patients who have received at least two prior therapies for metastatic disease.

Overall,Gilead Sciences' commitment to innovation has led it to become one of the most respected names in biopharmaceuticals today. With its focus on developing breakthrough therapies that can transform patient care across multiple therapeutic areas like infectious diseases including viral infections like COVID-19 , oncology & inflammation/respiratory diseases ,the future looks bright for this pioneering company.


In conclusion,Gilead Science’s dedication towards discovering new ways through which they can help people live better lives through their innovative medicines makes them stand out among other pharmaceutical companies globally.Their continuous investment into research & development ensures that they remain ahead when it comes down to providing solutions towards unmet medical needs.Given their track record,it’s no surprise why many people trust them when it comes down finding effective solutions towards various health conditions .